Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

Key Points • TIM-3 is the only immune-checkpoint receptor consistently overexpressed in patients with CML who relapse after TKI cessation.• Overexpression of TIM-3 provides a rationale to test TIM-3 inhibitors to modify treatment-free remission outcomes.

[1]  D. Mclornan,et al.  Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype , 2022, British journal of haematology.

[2]  S. Gill,et al.  The promise and perils of immunotherapy. , 2021, Blood advances.

[3]  Y. Kikushige.  TIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways , 2021, Cancer science.

[4]  M. Copland,et al.  Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape , 2021, Leukemia.

[5]  Lauren C. Chong,et al.  Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma , 2021, medRxiv.

[6]  B. Bastidas-Ramírez,et al.  Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD‐1/PD‐L1 axis , 2020, Clinical and experimental immunology.

[7]  Zhenyi Jin,et al.  Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia , 2020, BioMed research international.

[8]  A. Anderson,et al.  Tim-3 finds its place in the cancer immunotherapy landscape , 2020, Journal for immunotherapy of cancer.

[9]  D. White,et al.  Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells , 2020, British journal of haematology.

[10]  K. Lindblad,et al.  Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. , 2020, Blood advances.

[11]  V. Rocha,et al.  Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial , 2019, Blood.

[12]  V. Kuchroo,et al.  TIM3 comes of age as an inhibitory receptor , 2019, Nature Reviews Immunology.

[13]  P. Couceiro,et al.  NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors , 2019, Front. Immunol..

[14]  S. Miyano,et al.  Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. , 2019, Blood advances.

[15]  A. Fischer,et al.  Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome , 2018, Nature Genetics.

[16]  W. Hiddemann,et al.  Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML , 2018, Leukemia.

[17]  T. Aittokallio,et al.  Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML , 2018, Leukemia.

[18]  J. Sakamoto,et al.  Final 3‐year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second‐line Treatment , 2018, Clinical lymphoma, myeloma & leukemia.

[19]  D. Sansom,et al.  CTLA-4: a moving target in immunotherapy. , 2018, Blood.

[20]  A. Hidalgo-Miranda,et al.  Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib , 2017, Cancer medicine.

[21]  A. Toubert,et al.  Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study , 2017, Haematologica.

[22]  R. Sandberg,et al.  Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia , 2017, Nature Medicine.

[23]  D. White,et al.  CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. , 2017, Blood.

[24]  C. Drake,et al.  LAG3 (CD223) as a cancer immunotherapy target , 2017, Immunological reviews.

[25]  A. Kulkarni,et al.  T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer , 2017, Molecular oncology.

[26]  G. Esendagli,et al.  Functional exhaustion of CD4+ T cells induced by co‐stimulatory signals from myeloid leukaemia cells , 2016, Immunology.

[27]  U. Olsson‐Strömberg,et al.  Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia , 2016, Leukemia.

[28]  Shiguang Zhu,et al.  Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. , 2016, Immunobiology.

[29]  T. Hughes,et al.  Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.

[30]  T. Miyamoto,et al.  Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia , 2015, Oncology.

[31]  H. Hou,et al.  TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals , 2015, European journal of immunology.

[32]  W. Fang,et al.  Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer , 2015, Oncotarget.

[33]  Curt I Civin,et al.  Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. , 2013, Blood.

[34]  Richard J. Jones,et al.  Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations , 2013, Oncotarget.

[35]  X. Lu,et al.  Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma , 2012, Hepatology.

[36]  Ash A. Alizadeh,et al.  Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker , 2011, Proceedings of the National Academy of Sciences.

[37]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[38]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[39]  David H. Lee,et al.  Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells , 2010, The Journal of Immunology.

[40]  菊繁 吉謙.  TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells , 2012 .